loading page

Combined use of Total Glucosides of Paeony and Hydroxychloroquine in Primary Sjögren’s Syndrome: A Systematic Review
  • Aiping zhang,
  • Shilei Chen,
  • Riyang Lin
Aiping zhang
Hangzhou Hospital of Traditional Chinese Medicine
Author Profile
Shilei Chen
Hangzhou Hospital of Traditional Chinese Medicine
Author Profile
Riyang Lin
Hangzhou Hospital of Traditional Chinese Medicine

Corresponding Author:[email protected]

Author Profile


Objective: To assess the effectiveness and safety of the total glucosides of paeony (TGP) combined with Hydroxychloroquine (HCQ) on the treatment of primary Sjögren’s syndrome (pSS) by conducting a meta-analysis. Methods: Eight databases were searched for randomized controlled trials reporting the use of TGP combined with HCQ for pSS, which are before May 10,2022. Meta analyses were performed on disappeared clinical symptoms (dry mouth, dry eyes),schirmer’s test, saliva flow test, erythrocyte sedimentation rate (ESR), index of immunoglobulin G(IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), and adverse events (AEs). The Revman 5.4 software was used for this Meta-analysis.Results: Seven RCTs which included 632 participants were identified.The pooled results showed significant differences in clinical symptoms disappear(dry mouth, dry eyes)(P=0.0004), IgM(P < 0.00001) , IgA(P < 0.00001) , salivary flow rate(P < 0.00001) and schirmer’s test(p=0.02) in the comparison of TGP combined with HCQ and HCQ alone. For the IgG and ESR, both pooled and subgroup analyses showed that TGP+HCQ was superior to HCQ alone. For the safety analysis, no significant differences in AEs(P=0.39) was revealed. The more frequently seen adverse reactions were diarrhea, vomit and there was no severe adverse events were reported in TGP+HCQ group. Conclusion: Therefore, TGP+HCQ can be considered to be a potentially valid and safe combination for the treatment of pSS in the clinic.
22 Apr 2023Submitted to Immunity, Inflammation and Disease
09 May 2023Submission Checks Completed
09 May 2023Assigned to Editor
09 May 2023Review(s) Completed, Editorial Evaluation Pending
15 May 2023Reviewer(s) Assigned
08 Jul 2023Editorial Decision: Revise Major
14 Sep 20231st Revision Received
16 Sep 2023Submission Checks Completed
16 Sep 2023Assigned to Editor
16 Sep 2023Review(s) Completed, Editorial Evaluation Pending
17 Sep 2023Reviewer(s) Assigned
30 Sep 2023Editorial Decision: Accept
Oct 2023Published in Immunity, Inflammation and Disease volume 11 issue 10. https://doi.org/10.1002/iid3.1044